Cancer Cure Research Latest Discovery

In a tireless pursuit to find more effective methods of treatment and cures for cancer patients, a research excursion has led to the latest discovery producing a new effective application to cancerous tumors with a promise of a hastier recovery for suffering patients. The Blush wood tree, native only to the northern region of Queensland, Australia, bears fruit which is a berry with special healing attributes.

Researchers would like to see the farming of the berry brought to other locations. The berry produces a natural combatant chemical compound that has now equipped scientists with a new weapon in the ongoing search for a cure and battle against the persistent foe. After an eight year study led by Dr. Glen Boyle from the QIMR Berghofer Medical Research Institute, researchers have tested a new drug known as EBC-46, derived from the rare berry. The company responsible for the creation of the drug is the Queensland biotechnology company EcoBiotics.

The continuous development of EBC-46, as a veterinary pharmaceutical, is done by EcoBiotics subsidiary company QBiotic. Current tests have been placed on dogs, cats and horses suffering from cancerous tumors in the neck and head regions, and have resulted in an unusually rapid dissipation of the infection. Out of 300 hundred cases the experimental drug has shown to relieve 75 percent of the test subjects’ variety tumors, skin cancers and melanomas.

The cures revolving the cancer fighting discovery yielded surprising visual results. The drug seems to take effect in different ways. The first is that it can kill tumor cells and cancer cell reproduction directly. Secondly, it cuts of air supply to the infected region. As this happens, this has proved to trigger the hosts own immune system adding in the fight by taking care of the cancer remnants.

According to Dr. Boyle discovery, other forms of cancer cure treatment take weeks before showing any signs of recovery whereas the latest results from the application of EBC-46 produces immediate visual effects; purpling of the area within minutes, and in a short time lapse of just a few days’ results in a blacking of the area leading to an ultimate falling off of the tumor itself. Under further observation there seems to be a limit to the berry derived drug.

Dr. Boyle explains the extent of the EBC-46 is limited to the direct application of accessible tumors only, furthermore, when applied to metastatic forms of cancer the drug took no effect but still may contain hope, as Dr. Boyle believes more research and study of the drug need to be done, prior to expanding its capabilities into other cancer cures. Despite the limitations of EBC-46, the drug is seen as a potential alternate option to surgery and not as a replacement to chemotherapy or radiation treatment.

Cancer cures are continuously being tested through this latest ground breaking discovery. For elderly patients that cannot undergo more chemotherapy, the use of the EBC-46 may be a more viable option for them, in an example posed by Dr. Boyle. As of yet there has been no human testing but the Biotech company, QBiotic, has obtained ethical approval to begin human trials in both Australia and the United States.

by Ernesto Perez

Sources:

The Blaze
7 News
QIMR Berghofer